WallStSmart

Masco Corporation (MAS)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Masco Corporation generates 138% more annual revenue ($7.68B vs $3.22B). WST leads profitability with a 16.9% profit margin vs 10.9%. MAS appears more attractively valued with a PEG of 1.87. MAS earns a higher WallStSmart Score of 67/100 (B-).

MAS

Strong Buy

67

out of 100

Grade: B-

Growth: 5.3Profit: 8.5Value: 5.0Quality: 7.5
Piotroski: 4/9Altman Z: 2.35

WST

Buy

65

out of 100

Grade: C+

Growth: 7.3Profit: 8.0Value: 2.7Quality: 8.5
Piotroski: 4/9Altman Z: 4.73
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for MAS.

WSTSignificantly Overvalued (-55.4%)

Margin of Safety

-55.4%

Fair Value

$158.40

Current Price

$314.50

$156.10 premium

UndervaluedFair: $158.40Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MAS3 strengths · Avg: 9.3/10
Return on EquityProfitability
84.6%10/10

Every $100 of equity generates 85 in profit

Debt/EquityHealth
-13.6410/10

Conservative balance sheet, low leverage

EPS GrowthGrowth
20.0%8/10

Earnings expanding 20.0% YoY

WST5 strengths · Avg: 9.0/10
EPS GrowthGrowth
56.1%10/10

Earnings expanding 56.1% YoY

Altman Z-ScoreHealth
4.7310/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.119/10

Conservative balance sheet, low leverage

Operating MarginProfitability
21.7%8/10

Strong operational efficiency at 21.7%

Revenue GrowthGrowth
21.0%8/10

Revenue surging 21.0% year-over-year

Areas to Watch

MAS2 concerns · Avg: 3.0/10
PEG RatioValuation
1.874/10

Expensive relative to growth rate

Free Cash FlowQuality
$-113.00M2/10

Negative free cash flow — burning cash

WST2 concerns · Avg: 2.0/10
PEG RatioValuation
3.162/10

Expensive relative to growth rate

P/E RatioValuation
44.1x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : MAS

The strongest argument for MAS centers on Return on Equity, Debt/Equity, EPS Growth.

Bull Case : WST

The strongest argument for WST centers on EPS Growth, Altman Z-Score, Debt/Equity. Profitability is solid with margins at 16.9% and operating margin at 21.7%. Revenue growth of 21.0% demonstrates continued momentum.

Bear Case : MAS

The primary concerns for MAS are PEG Ratio, Free Cash Flow.

Bear Case : WST

The primary concerns for WST are PEG Ratio, P/E Ratio. A P/E of 44.1x leaves little room for execution misses.

Key Dynamics to Monitor

MAS profiles as a value stock while WST is a growth play — different risk/reward profiles.

MAS carries more volatility with a beta of 1.31 — expect wider price swings.

WST is growing revenue faster at 21.0% — sustainability is the question.

WST generates stronger free cash flow (47M), providing more financial flexibility.

Bottom Line

MAS scores higher overall (67/100 vs 65/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Masco Corporation

INDUSTRIALS · BUILDING PRODUCTS & EQUIPMENT · USA

Masco Corporation is a manufacturer of products for the home improvement and new home construction markets.

Visit Website →

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?